This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

Bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) is an investigational, once-daily, single-tablet combination therapy developed by Gilead Sciences to treat HIV-1 infection in adults who are already virologically suppressed — meaning people whose HIV is effectively controlled by their current treatment. Think of it as a consolidation pill: instead of juggling multiple tablets from a complicated regimen, a patient could potentially switch to a single pill that contains two distinct active ingredients working in tandem to keep the virus in check. Both bictegravir and lenacapavir are already approved individually or as part of other combinations, and this new formulation packages them together at specific doses (bictegravir 75 mg and lenacapavir 50 mg) optimized for daily oral use.